Vanda Pharmaceuticals (VNDA) is now covered by Truist Financial Corporation. They set a "buy" rating and a $18.00 price target on the stock.
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years [Yahoo! Finance]
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis [Yahoo! Finance]